Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1151 to 1200 of 1283 results for long term conditions

  1. What are the service and service user characteristics of highly specialist and longer-term high-dependency rehabilitation units that are associated with better outcomes?

    service and service user characteristics of highly specialist and longer-term high-dependency rehabilitation units that are associated...

  2. Autologous blood injection for tendinopathy (IPG438)

    Evidence-based recommendations on autologous blood injection for tendinopathy. This involves supplying the tendon with growth factors that start the healing process.

  3. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

  4. High-sensitivity troponin tests for the early rule out of NSTEMI (DG40)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction)

  5. Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)

    NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma

  6. Cardiac rehabilitation:- Is an 8-week, comprehensive, multidisciplinary, cardiac rehabilitation service more clinically and cost effective for managing stable angina than current clinical practice?

    rehabilitation programmes are an established treatment strategy for certain heart conditions, such as for people who have had a heart...

  7. Immunosuppressive therapy for kidney transplant in children and young people (TA482)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

  8. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

  9. Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

    Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.

  10. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources

  11. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

  12. Blood pressure targets: What is the clinical and cost effectiveness of a lower blood pressure treatment target relative to the standard blood pressure treatment target for people with aneurysmal subarachnoid haemorrhage?

    other conditions after discharge from hospital. Full details of the evidence and the committee's discussion are in evidence review Q:...

  13. Clostridioides difficile infection: antimicrobial prescribing (NG199)

    This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

  14. DOAC Dipstick for detecting direct oral anticoagulants (MIB248)

    NICE has developed a medtech innovation briefing (MIB) on DOAC Dipstick for detecting direct oral anticoagulants .

  15. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    Evidence-based recommendations on atezolizumab (Tecentriq) for adjuvant treatment of resected non-small-cell lung cancer in adults.

  16. Sofosbuvir for treating chronic hepatitis C (TA330)

    Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

  17. Urolift – a community-based alternative treatment for Benign Prostatic Obstruction (BPO)

    BPO describes the cause of lower urinary tract symptoms from BPH and is the term used to describe the patient group in this case study.

  18. Transition in special groups: looked-after young people:- What is the most effective way of supporting care leavers in transition from children's to adults' health services?

    birth parents in the management of childhood-onset long-term physical and mental health conditions is...

  19. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for treating follicular lymphoma in adults.

  20. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

  21. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

  22. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

  23. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)

    Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in

  24. Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

    Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.

  25. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

  26. Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

    Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults.

  27. Sarilumab for moderate to severe rheumatoid arthritis (TA485)

    Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.

  28. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  29. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

  30. Vaccine uptake in the general population (NG218)

    This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.

  31. Domestic Abuse, Recovering Together (DART): A robustly evaluated intervention found to strengthen the mother-child relationship

    impact of domestic abuse. The programme aims to address the immediate and long-term negative effects that children are...

  32. Integrated Respiratory Action Network Group for patients with Chronic Obstructive Pulmonary Disease (COPD)

    (COPD) in 2014/2015. Wolverhampton city is a deprived area with a higher long-term unemployment and smoking prevalence than...

  33. Fasciotens for abdominal wall closure (MIB321)

    NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .

  34. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

  35. Novii Wireless Patch System for maternal and fetal monitoring (MIB228)

    NICE has developed a medtech innovation briefing (MIB) on Novii Wireless Patch System for maternal and fetal monitoring .

  36. User guide for the cost comparison company evidence submission template (PMG32)

    User guide for the cost comparison company evidence submission template

  37. FreeStyle Libre for glucose monitoring (MIB110)

    NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .

  38. Artificial intelligence for analysing chest CT images (MIB243)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .

  39. Dexcom G6 for real-time continuous glucose monitoring (MIB233)

    NICE has developed a medtech innovation briefing (MIB) on Dexcom G6 for real-time continuous glucose monitoring .

  40. microINR for anticoagulation therapy (MIB257)

    NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .

  41. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

  42. Insertion of a magnetic bead band for faecal incontinence (IPG483)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.

  43. ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment (MIB39)

    NICE has developed a medtech innovation briefing (MIB) on ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment

  44. What interventions are effective and cost effective at raising awareness of the health risks of damp and mould in the home?

    quality is linked to a range of health problems. This includes respiratory conditions such as a cough, wheezing or asthma, and allergic...

  45. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

  46. For which people with impetigo are antiseptics as effective as antibiotics?

    their use. Based on the available evidence, the committee agreed that the long-term benefits of good antimicrobial...

  47. Dramatherapy in Early Intervention in Psychosis

    treatment and are more likely to engage in standard rehabilitation with better long term outcomes Addresses this...

  48. Icare rebound tonometer to measure intraocular pressure (MIB57)

    NICE has developed a medtech innovation briefing (MIB) on the Icare rebound tonometer to measure intraocular pressure